[HTML][HTML] Association of disease-modifying therapies with COVID-19 susceptibility and severity in patients with multiple sclerosis: a systematic review and network meta …

M Barzegar, S Houshi, E Sadeghi… - Multiple sclerosis …, 2022 - hindawi.com
Background. We conducted this study to assess the effect of disease-modifying therapies
(DMTs) on coronavirus disease (COVID-19) susceptibility and severity in people with …

MIND diet adherence might be associated with a reduced odds of multiple sclerosis: results from a case–control study

M Noormohammadi, Z Ghorbani… - Neurology and …, 2022 - Springer
Abstract Introduction The Mediterranean Dietary Approaches to the Stop Hypertension
(DASH) Intervention for Neurodegenerative Delay (MIND) diet has been shown to have …

The prevalence of depression and anxiety among Iranian people with multiple sclerosis: A systematic review and meta-analysis.

A Shafiee, H Soltani, MMT Athar, K Jafarabady… - Multiple Sclerosis and …, 2023 - Elsevier
Background There is significant inconsistency regarding the prevalence rate of depression
and anxiety among people with multiple sclerosis (MS) in Iran. We sought to conduct this …

Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics

F Ghadiri, MA Sahraian, N Razazian, F Ashtari… - Multiple sclerosis and …, 2023 - Elsevier
Background Today, it is estimated that around 5% of multiple sclerosis (MS) patients are in
the late-onset category (age at disease onset≥ 50). Diagnosis and treatment in this group …

Relationship between medical history and multiple sclerosis: a-case-control study

M Ghazaiean, H Darvishi-Khezri, SM Baghbanian - Medicine, 2023 - journals.lww.com
This project sought to explore the potential association between medical history and the
development of multiple sclerosis (MS) by conducting a retrospective study. This population …

Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: A multicentral-triple blind …

S Jafari Karegar, N Aryaeian, G Hajiluian… - Frontiers in …, 2023 - frontiersin.org
Background Multiple sclerosis (MS) is a chronic autoimmune disease. Ellagic acid is a
natural polyphenol and affects the fate of neurons through its anti-inflammatory and …

Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years

F Ghadiri, MA Sahraian, SM Baghbanian… - Multiple sclerosis and …, 2022 - Elsevier
Background Iran, as a middle income country, is one of the places with high and rising
prevalence of multiple sclerosis (MS). Regarding the substantial economic burden …

Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: A regional survey-based study

M Zeineddine, A Al-Hajje, P Salameh, A Helme… - Multiple sclerosis and …, 2023 - Elsevier
Background Multiple sclerosis (MS) management varies markedly between different
countries of the Middle East and North Africa (MENA) region based on the availability and …

Social stigma and its relationship with quality of life in multiple sclerosis patients

N Sharifi, V Kohpeima Jahromi, R Zahedi, S Aram… - BMC neurology, 2023 - Springer
Introduction Multiple sclerosis (MS) is the most prevalent disease of the central nervous
system that affects the behavioral characteristics and lifestyle of patients. This study aimed to …

[HTML][HTML] Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple …

SJ Karegar, N Aryaeian, G Hajiluian, K Suzuki… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background Multiple sclerosis (MS) is a chronic autoimmune disease. Ellagic acid is a
natural polyphenol and affects the fate of neurons through its anti-inflammatory and …